RDDT · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Total Revenue | $2.20B | $1.30B | $804.03M | $666.70M |
| Cost of Revenue | $194.22M | $123.59M | $111.01M | $104.80M |
| Research & Development | $783.14M | $935.15M | $438.35M | $365.16M |
| Selling, General & Administrative | $279.30M | $451.45M | $164.66M | $143.82M |
| Operating Expenses | $1.76B | $1.86B | $944.19M | $838.86M |
| Operating Income | $441.98M | -$560.57M | -$140.16M | -$172.16M |
| Other Income / (Expense) | $86.71M | $75.36M | $53.14M | $14.23M |
| Income Before Taxes | $528.69M | -$485.21M | -$87.02M | -$157.93M |
| Provision for Income Taxes | -$1.03M | -$931.00K | $3.80M | $622.00K |
| Net Income | $530.00M | -$484.00M | -$90.82M | -$158.55M |
| Basic EPS | $2.84 | -$3.33 | -$1.54 | -$2.77 |
| Diluted EPS | $2.62 | -$3.33 | -$1.54 | -$2.77 |
| Basic Shares Outstanding | 186.38M | 145.47M | 59.14M | 57.25M |
| Diluted Shares Outstanding | 202.11M | 145.47M | 59.14M | 57.25M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $5.19 | $4.33 | $5.73 | 12 | ↑7 ↓1 |
| Dec 2027 | $6.86 | $4.35 | $8.59 | 13 | ↑8 ↓1 |
| Dec 2028 | $8.78 | $6.36 | $11.10 | 9 | ↑5 ↓1 |
| Dec 2029 | $11.15 | $8.27 | $14.73 | 4 | ↑3 ↓0 |